# Solventum (SOLV) Financial Model Free Excel 3-statement financial model and company analysis for Solventum. - Canonical: https://finamodel.com/companies/solventum - Industry: Medical Devices - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/SOLV.xlsx ## Model Purpose This model provides a comprehensive equity valuation and scenario planning tool for an analyst evaluating Solventum's standalone earnings power, deleveraging trajectory, and margin expansion potential following its spin-off from 3M and the transformational divestiture of its Purification and Filtration business. ## Company Overview Solventum Corporation (SOLV) is a global healthcare company that develops, manufactures, and commercialises a broad portfolio of medical, dental, and health information systems. Spun off from 3M on April 1, 2024, the company provides advanced wound care solutions, dental restorative products, and AI-powered clinical documentation software. Business segments include: * MedSurg (approx. 58% of revenue) * Dental Solutions (approx. 16% of revenue) * Health Information Systems (HIS) (approx. 16% of revenue) * Purification and Filtration (divested in September 2025; historically approx. 10% of revenue) The company generates approximately 56% of its sales in the United States and 44% internationally. Solventum operates a mixed business model comprising high-margin consumables, specialised medical hardware, and recurring software subscriptions. Its competitive position is anchored by market leadership in advanced wound care (V.A.C. therapy) and clinical documentation software integrated with major electronic health record providers like Epic. Recent major events include the April 2024 spin-off from 3M, the September 2025 divestiture of the Purification and Filtration business to Thermo Fisher Scientific for approximately $4 billion, and the late 2025 acquisition of Acera Surgical for $776 million. ## Revenue Deep Dive ### MedSurg * **Segment name:** MedSurg * **Revenue driver formula:** Procedure Volumes x Average Selling Price per Unit * **Historical growth rate:** 2% to 4% organic CAGR * **Key growth levers and headwinds:** Driven by elective surgery volumes, infection prevention protocols, and the integration of Acera Surgical. Headwinds include hospital capital expenditure constraints and planned SKU rationalisation. * **Pricing dynamics:** Largely contractual with group purchasing organisations (GPOs) and hospital networks. * **Revenue recognition notes:** Recognised at the point in time when control of the product transfers to the customer. * **Seasonality:** Q4 is typically the strongest quarter due to the exhaustion of patient deductibles driving higher elective procedure volumes. ### Dental Solutions * **Segment name:** Dental Solutions * **Revenue driver formula:** Dental Visit Volumes x Consumables Usage per Visit * **Historical growth rate:** 3% to 5% organic CAGR * **Key growth levers and headwinds:** Growth is driven by demand for premium restorative materials (Filtek) and orthodontic solutions (Clarity). Highly sensitive to consumer discretionary spending and macroeconomic conditions. * **Pricing dynamics:** Competitive pricing in a fragmented market, with premium pricing power in branded restorative materials. * **Revenue recognition notes:** Point-in-time recognition upon shipment to dental distributors. * **Seasonality:** Relatively stable, with slight dips in summer months due to holiday schedules. ### Health Information Systems (HIS) * **Segment name:** Health Information Systems * **Revenue driver formula:** Number of Hospital Clients x Annual Subscription Value * **Historical growth rate:** 5% to 7% organic CAGR * **Key growth levers and headwinds:** Driven by hospital adoption of AI-powered autonomous coding and clinical documentation software. Headwinds include long enterprise sales cycles. * **Pricing dynamics:** Subscription-based pricing with multi-year contracts. * **Revenue recognition notes:** Software-as-a-Service (SaaS) revenue is recognised rateably over the contract term. * **Seasonality:** Q4 sees higher bookings, but revenue recognition is smoothed over the year. ### Purification and Filtration (Divested) * **Segment name:** Purification and Filtration * **Revenue driver formula:** Legacy run-rate (Divested in Q3 2025) * **Historical growth rate:** 4% to 6% prior to sale * **Key growth levers and headwinds:** N/A (Business sold to Thermo Fisher). * **Pricing dynamics:** N/A * **Revenue recognition notes:** Ceased contributing to consolidated revenue in September 2025. * **Seasonality:** N/A ## Cost Structure ### Variable Costs / COGS * **Line-by-line breakdown:** Raw materials, direct manufacturing labour, overhead, freight, and mark-ups from 3M supply agreements. * **Gross margin range:** 53% to 55% historically. * **Key input costs and commodity exposures:** Resins, specialty chemicals, and electronic components. * **How COGS scales with revenue:** Largely linear for MedSurg and Dental, but HIS exhibits high gross margin operating leverage as software revenue scales. ### Operating Expenses * **R&D:** Typically 8% to 9% of revenue. Covers clinical trials, software development for HIS, and material science innovation. * **SG&A:** Typically 35% to 37% of revenue. Includes sales force compensation, marketing, and significant public company stand-up costs following the 3M spin-off. * **Depreciation & Amortisation:** Approximately 6% to 8% of revenue, heavily weighted towards amortisation of acquired intangibles. * **Stock-Based Compensation:** Approximately 1% to 2% of revenue. * **Restructuring / one-time charges:** High frequency in 2024 and 2025 due to spin-off separation costs, rebranding, and portfolio optimisation (SKU exits). ### Margin Profile * **Gross margin:** 53% to 55%. * **EBITDA margin:** 24% to 26% (Adjusted). * **Operating margin:** 20% to 22% (Adjusted). GAAP operating margin in 2025 was heavily distorted by the gain on the sale of the Purification and Filtration business. * **Margin trend:** Expected to expand gradually as standalone costs normalise and the lower-margin SKU rationalisation programme concludes. ## Balance Sheet Structure * **Total assets:** Approximately $14 billion to $15 billion. * **Key asset categories:** Goodwill, intangible assets, property, plant and equipment, and inventory. * **Goodwill & intangibles as % of total assets:** Over 60%, reflecting legacy 3M acquisitions (e.g., Acelity/KCI) and the recent Acera Surgical deal. * **Working capital profile:** * **Days Sales Outstanding (DSO):** 45 to 55 days. * **Days Inventory Outstanding (DIO):** 80 to 95 days. * **Days Payable Outstanding (DPO):** 50 to 60 days. * **Net working capital as % of revenue:** 15% to 20%. * **Is working capital positive or negative?** Positive. The company requires working capital to fund inventory for its MedSurg and Dental segments. * **PP&E:** Manufacturing facilities and specialised tooling. Maintenance capex is a significant component. * **Right-of-use assets / operating leases:** Material but manageable, primarily related to office space and warehouse facilities. ## Capital Expenditure & Investment * **Capex as % of revenue:** 4% to 5%. * **Maintenance capex vs. growth capex:** Approximately 60% maintenance and IT infrastructure (stand-up costs), 40% growth. * **Major capex programmes underway or planned:** Establishing independent IT systems and ERP infrastructure separate from 3M. * **Capitalised software / development costs if material:** Material for the HIS segment, capitalised and amortised over 3 to 5 years. * **M&A pattern:** Active portfolio management. Divested a major non-core asset (Purification and Filtration) and executed a bolt-on acquisition (Acera Surgical) in 2025. * **Typical acquisition multiple paid:** 3x to 5x revenue for high-growth medtech assets. ## Debt & Capital Structure * **Total debt:** Approximately $4.2 billion at the end of 2025 (reduced from $8.3 billion at the spin-off). * **Debt/EBITDA ratio:** Approximately 1.9x (down from over 3.0x at spin-off). * **Credit rating:** Investment grade profile targeted. * **Key debt instruments:** Senior unsecured notes and a $2.0 billion commercial paper programme. * **Maturity profile:** Staggered maturities established during the 2024 spin-off debt issuance. * **Interest rate profile:** Predominantly fixed-rate senior notes. * **Covenants:** Standard investment-grade financial covenants. * **Share repurchase programme:** Not currently active; management priority is debt paydown and bolt-on M&A. * **Dividend policy:** No dividend currently paid; capital is prioritised for deleveraging. ## Cash Flow Characteristics * **Operating cash flow conversion:** Historically strong, but depressed in 2024 and 2025 due to spin-off costs and working capital build. * **Free cash flow margin:** Currently low (guidance of ~$200 million FCF in 2026 on ~$8 billion revenue, or ~2.5% margin) due to heavy interest expense and separation capex. * **Major non-cash items that bridge net income to OCF:** Depreciation, amortisation of intangibles, stock-based compensation, and the 2025 gain on the sale of the Purification business. * **Working capital cash flow impact:** A use of cash during the initial spin-off phase as the company built independent inventory buffers. * **Capex intensity:** Moderate (4% to 5% of revenue). * **Cash tax rate vs. GAAP effective tax rate:** Cash taxes are generally lower than GAAP taxes due to the amortisation of tax-deductible goodwill from historical asset purchases. ## Sheet Structure 1. **Assumptions**: Hardcoded inputs for macroeconomic drivers, segment growth rates, margin targets, and capital allocation policies. 2. **Scenarios**: Scenario manager toggling Base, Bull, and Bear cases for organic growth and SKU rationalisation impacts. 3. **Income Statement**: Consolidated P&L mirroring the 10-K, including specific lines for "Gain on sale of business" and "Restructuring charges". 4. **Revenue Build**: Segment-level revenue forecasting for MedSurg, Dental Solutions, HIS, and All Other. Purification and Filtration must be isolated and zeroed out post-Q3 2025. 5. **Cost Build**: Detailed breakdown of COGS, SG&A, and R&D, separating ongoing operations from temporary stand-up costs. 6. **Balance Sheet**: Standard assets, liabilities, and equity, with detailed schedules for Goodwill and Intangibles. 7. **Working Capital**: Schedules for Accounts Receivable, Inventory, and Accounts Payable driven by DSO, DIO, and DPO. 8. **PP&E & Intangibles**: Capex, depreciation, and amortisation waterfall schedules. 9. **Debt Schedule**: Tranche-by-tranche debt tracking, interest expense calculation, and commercial paper balances. 10. **Cash Flow Statement**: Indirect method bridging Net Income to Free Cash Flow, explicitly showing divestiture proceeds. 11. **Valuation**: DCF model, WACC calculation, and comparable company multiples. ## Key Financial Relationships 1. `MedSurg Revenue = Prior Year MedSurg Revenue * (1 + MedSurg Organic Growth Rate) - SKU Rationalisation Impact` 2. `Dental Solutions Revenue = Prior Year Dental Revenue * (1 + Dental Organic Growth Rate)` 3. `HIS Revenue = Prior Year HIS Revenue * (1 + HIS Organic Growth Rate)` 4. `Purification & Filtration Revenue = 0` (For all periods after September 2025) 5. `Total Net Sales = MedSurg Revenue + Dental Solutions Revenue + HIS Revenue + All Other Revenue` 6. `Gross Profit = Total Net Sales * Consolidated Gross Margin %` 7. `SG&A Expense = (Total Net Sales * SG&A % of Sales) + Stand-up Costs` 8. `Adjusted Operating Income = Gross Profit - SG&A Expense (excluding Stand-up Costs) - R&D Expense` 9. `Interest Expense = Average Total Debt * Blended Interest Rate` 10. `Free Cash Flow = Operating Cash Flow - Capital Expenditures - Capitalised Software Costs` ## Cross-Sheet Dependencies * The **Revenue Build** sheet feeds the top line of the **Income Statement**. * The **Cost Build** sheet calculates operating expenses which feed the **Income Statement**. * Net Income from the **Income Statement** is the starting point for the **Cash Flow Statement**. * Capital Expenditures from the **Cash Flow Statement** feed the **PP&E & Intangibles** sheet, which calculates Depreciation and Amortisation. * Depreciation and Amortisation flow back to the **Cash Flow Statement** (as non-cash add-backs) and the **Income Statement** (within operating expenses). * The **Debt Schedule** calculates Interest Expense, which feeds the **Income Statement**. This creates a circular reference if debt paydown is driven by cash sweep mechanics. * Ending cash from the **Cash Flow Statement** feeds the **Balance Sheet**. ## Sign Convention * Revenue and Asset balances are positive. * Expenses, Capital Expenditures, and Liability balances are positive in their respective build schedules. * On the Income Statement, expenses are subtracted from revenue (entered as positive numbers, formula subtracts them). * On the Cash Flow Statement, cash inflows are positive, and cash outflows (e.g., Capex, debt repayment) are negative. ## Things Most Likely to Go Wrong * Failing to zero out the Purification and Filtration segment revenue from Q4 2025 onwards will massively overstate future revenue. * GAAP Operating Margin in 2025 includes a multi-billion dollar gain on the sale of the Purification business; using GAAP margins to forecast future profitability will result in severe errors. The model must use Adjusted Operating Margin. * The company is actively exiting low-margin SKUs, which creates a 100 bps drag on reported revenue growth in 2026. The model must separate underlying organic growth from the SKU exit impact. * Interest expense will drop significantly in 2026 compared to 2024 due to the $4.1 billion debt paydown in late 2025. Using historical effective interest rates on historical debt balances will understate 2026 earnings. * Stand-up costs related to the 3M spin-off inflate SG&A in 2024 and 2025. These must be modelled as non-recurring or fading over time to capture true long-term margin potential. * The company purchases products from 3M under transition supply agreements, which include mark-ups that temporarily depress gross margins. * Free cash flow in 2026 is guided to only ~$200 million despite high adjusted earnings, due to heavy separation capex and working capital needs. Do not assume standard net income-to-FCF conversion ratios in the near term. * 3M retains a 19.9% stake in Solventum, which may create an equity overhang, though this does not impact the fundamental enterprise valuation. ## Validation Checks * Purification and Filtration revenue must equal $0 in 2026 and beyond. * Total Debt should be approximately $4.2 billion at the start of 2026. * Debt/EBITDA should remain below 2.0x in the forecast period based on management targets. * Consolidated 2026 organic revenue growth should fall between 2.0% and 3.0%. * Adjusted Operating Margin should be in the 20% to 22% range. * Free Cash Flow for 2026 should calculate to approximately $200 million. * The Balance Sheet must balance: Total Assets = Total Liabilities + Shareholders' Equity in all periods. * Diluted share count should remain relatively flat at approximately 173.4 million, as no major buybacks are planned. ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | MedSurg Organic Growth | 3.0 | % | Midpoint of management long-term expectations | | Dental Solutions Organic Growth | 4.0 | % | Midpoint of historical segment performance | | HIS Organic Growth | 5.0 | % | Driven by AI documentation adoption | | SKU Rationalisation Impact | -1.0 | % | Management guidance for 2026 revenue drag | | Consolidated Gross Margin | 53.5 | % | Based on 2025 actuals and ongoing supply agreements | | SG&A as % of Revenue | 36.0 | % | Reflects ongoing standalone public company costs | | R&D as % of Revenue | 8.5 | % | Consistent with historical medtech investment levels | | Effective Tax Rate | 19.0 | % | Based on management adjusted tax rate guidance | | Diluted Shares Outstanding | 173.4 | Millions | Actual Q4 2025 share count | | Average Interest Rate on Debt | 5.5 | % | Blended rate on remaining senior notes | | Days Sales Outstanding (DSO) | 50 | Days | Historical average | | Days Inventory Outstanding (DIO) | 85 | Days | Historical average | | Days Payable Outstanding (DPO) | 55 | Days | Historical average | | Capex as % of Revenue | 4.5 | % | Elevated near-term due to IT stand-up costs | | WACC | 8.5 | % | Standard medtech discount rate | | Terminal Growth Rate | 2.5 | % | Long-term GDP and healthcare spending growth | ## Data Sources & Benchmarks * **SEC Filings:** Solventum Form 10-K (filed February 2026 for FY2025), Form 10 (Spin-off registration). * **Investor Relations:** Solventum Q4 2025 Earnings Presentation and 2026 Guidance Call. * **Key Peers:** Medtronic (MDT), Zimmer Biomet (ZBH), Dentsply Sirona (XRAY), 3M (MMM). * **Industry Data:** Epic Systems market share reports (for HIS segment), global elective surgery volume data. * **Consensus Estimates:** FactSet or Bloomberg for forward EPS and revenue estimates. ## Sources * Solventum Corporation SEC Form 10-K for the year ended December 31, 2025 (sec.gov). * Solventum Q4 2025 Earnings Release and Financial Update (investors.solventum.com). * "Solventum (SOLV): The 3M Spin-Off That Found Its Rhythm" - Chronicle Journal (January 2026). * "Is 3M Spinoff Solventum a Buy?" - The Motley Fool (May 2024). * "3M To Spin-Off Solventum Unit Tax-Free To Shareholders" - Forbes (February 2024). --- ## Frequently asked questions ### What is Solventum's primary business focus after its spin-off from 3M? Solventum Corporation (SOLV) is a global healthcare company specializing in medical, dental, and health information systems. It provides advanced wound care solutions, dental restorative products, and AI-powered clinical documentation software, having spun off from 3M in April 2024. ### How does Solventum generate revenue across its different business segments? Solventum generates revenue through its MedSurg (approx. 58%), Dental Solutions (approx. 16%), and Health Information Systems (HIS) (approx. 16%) segments. Its business model includes high-margin consumables, specialized medical hardware, and recurring software subscriptions. ### What is Solventum's capital expenditure strategy, and what drives its capex spending? Solventum's capital expenditure is approximately 4% to 5% of revenue, with about 60% allocated to maintenance and IT infrastructure. Major capex programs are focused on establishing independent IT systems and ERP infrastructure following its spin-off from 3M. ### What is Solventum's working capital profile, and why is it positive? Solventum maintains a positive working capital profile, with net working capital representing 15% to 20% of revenue. This positive working capital is necessary to fund inventory for its MedSurg and Dental segments, supporting its operational needs. ### What are the key considerations for an analyst evaluating Solventum's equity valuation? An analyst evaluating Solventum's equity valuation should focus on its standalone earnings power, deleveraging trajectory, and margin expansion potential. The company's recent spin-off from 3M and the divestiture of its Purification and Filtration business are critical factors in this assessment. ### What is the main purpose of a financial model for analyzing Solventum's performance? A financial model for Solventum aims to provide a comprehensive equity valuation and scenario planning tool. It helps analysts assess the company's financial health, post-spin-off performance, and strategic direction. [Interactive forecast calculator](https://finamodel.com/companies/solventum/forecast)